[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 124, "companyOfficers": [{"maxAge": 1, "name": "Ms. Andrea  Paul J.D.", "age": 43, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 682466, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Julie M. Eastland M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1964, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Vincent  Vultaggio", "age": 41, "title": "VP of Finance & Interim Principal Accounting Officer", "yearBorn": 1983, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Lackner Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Chang", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ingmar  Bruns M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Haibo  Wang", "title": "Chief Business Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.81, "open": 1.86, "dayLow": 1.76, "dayHigh": 1.88, "regularMarketPreviousClose": 1.81, "regularMarketOpen": 1.86, "regularMarketDayLow": 1.76, "regularMarketDayHigh": 1.88, "payoutRatio": 0.0, "beta": 1.754, "forwardPE": -0.49579832, "volume": 641262, "regularMarketVolume": 641262, "averageVolume": 1862241, "averageVolume10days": 860110, "averageDailyVolume10Day": 860110, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 126139760, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 16.265, "priceToSalesTrailing12Months": 3.1099546, "fiftyDayAverage": 2.2486, "twoHundredDayAverage": 3.7381, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -221846240, "profitMargins": 0.0, "floatShares": 44467472, "sharesOutstanding": 71265400, "sharesShort": 5174424, "sharesShortPriorMonth": 4848542, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.0726, "heldPercentInsiders": 0.15581, "heldPercentInstitutions": 0.93331003, "shortRatio": 2.27, "shortPercentOfFloat": 0.1462, "impliedSharesOutstanding": 72263504, "bookValue": 4.98, "priceToBook": 0.3554217, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -179284000, "trailingEps": -2.5, "forwardEps": -3.57, "enterpriseToRevenue": -5.47, "enterpriseToEbitda": 1.067, "52WeekChange": -0.87229437, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 1.77, "targetHighPrice": 10.0, "targetLowPrice": 2.2, "targetMeanPrice": 6.27, "targetMedianPrice": 6.0, "recommendationMean": 2.18182, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 391252000, "totalCashPerShare": 5.49, "ebitda": -207958000, "totalDebt": 43266000, "quickRatio": 7.13, "currentRatio": 7.294, "totalRevenue": 40560000, "debtToEquity": 12.211, "revenuePerShare": 0.572, "returnOnAssets": -0.2524, "returnOnEquity": -0.42891, "grossProfits": 40560000, "freeCashflow": -81906872, "operatingCashflow": -171756992, "grossMargins": 1.0, "ebitdaMargins": 0.0, "operatingMargins": -5.1594396, "financialCurrency": "USD", "symbol": "ZNTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1585920600000, "postMarketChangePercent": 1.69491, "postMarketPrice": 1.8, "postMarketChange": 0.03, "regularMarketChange": -0.03999996, "regularMarketDayRange": "1.76 - 1.88", "marketState": "CLOSED", "exchange": "NGM", "messageBoardId": "finmb_647536411", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1862241, "fiftyTwoWeekLowChange": 0.15999997, "fiftyTwoWeekLowChangePercent": 0.09937886, "fiftyTwoWeekRange": "1.61 - 16.265", "fiftyTwoWeekHighChange": -14.494999, "fiftyTwoWeekHighChangePercent": -0.89117736, "fiftyTwoWeekChangePercent": -87.22944, "earningsTimestampStart": 1742381940, "earningsTimestampEnd": 1743508800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.5, "epsForward": -3.57, "epsCurrentYear": -2.40205, "priceEpsCurrentYear": -0.7368706, "fiftyDayAverageChange": -0.47860003, "fiftyDayAverageChangePercent": -0.21284355, "twoHundredDayAverageChange": -1.9681001, "twoHundredDayAverageChangePercent": -0.5264974, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.2 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1741989906, "regularMarketTime": 1741982401, "regularMarketChangePercent": -2.2099428, "regularMarketPrice": 1.77, "displayName": "Zentalis Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]